LIXI
Lixisenatide
A synthetic peptide based on exendin-4: the C-terminal proline is deleted and six lysine residues are added in its place. It binds the GLP-1 receptor. The polylysine tail is the structural difference between it and exenatide.
Lixisenatide has 66 registered human studies on ClinicalTrials.gov, reaching phase 4, covering 26,219 planned or enrolled participants across the 65 studies that published a figure. An FDA-approved product contains Lixisenatide — SOLIQUA 100/33 (BLA208673). 538 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Lixisenatide; the registry search is fuzzy, so every match is re-checked. None of this says whether Lixisenatide works or is safe.
FDA status
Approved
Human studies
66
Furthest phase
Phase 4
Papers, 10 yr
538
Readership
462
monthly average, Feb–Jul 2026
Tracking since 2026-08-02 · About this data
What has actually been tested in humans
An approved product exists
66
Registered human studies
Phase 4
Furthest phase reached
26,219
Planned or enrolled participants, across 65 studies that published a figure
Approved
FDA-approved product — SOLIQUA 100/33
75 loose registry matches were checked and 66 confirmed — 9 named something else and were discarded. We count a study only when Lixisenatide is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Lixisenatide is, and what it has been studied for
Lixisenatide is classified by ChEMBL as a protein, and appears in trial registrations under AVE-0010 and AVE0010. Its FDA substance identifier is 74O62BB01U.
Across 66 registered trials, it has been studied in Type 2 Diabetes Mellitus and Diabetes Mellitus, Type 2. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by Sanofi and Profil Institut für Stoffwechselforschung GmbH among others. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Lixisenatide reached Phase 4 across 66 registered trials.
An FDA-approved product contains Lixisenatide. Approval covers a specific product for a specific use — it is not a verdict on the molecule.
Is anyone studying Lixisenatide?
Papers published each year that name Lixisenatide in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 96 | 3 | Yes |
| 2018 | 77 | 4 | Yes |
| 2019 | 79 | 3 | Yes |
| 2020 | 61 | 0 | Yes |
| 2021 | 50 | 1 | Yes |
| 2022 | 40 | 2 | Yes |
| 2023 | 44 | 1 | Yes |
| 2024 | 48 | 1 | Yes |
| 2025 | 66 | 3 | Yes |
| 2026 | 54 | 1 | No |
538 papers and 19 registered trials between 2017 and 2026. A paper counts when “Lixisenatide” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Lixisenatide
538 indexed papers name Lixisenatide in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Trial of Lixisenatide in Early Parkinson's Disease
- GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
- Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
- Lixisenatide
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- Lixisenatide
- Lixisenatide
- Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients
Collected 2026-08-02from PubMed, phrase-matched on “Lixisenatide” in title and abstract. Run the same search.
About Lixisenatide
A synthetic peptide based on exendin-4: the C-terminal proline is deleted and six lysine residues are added in its place. It binds the GLP-1 receptor. The polylysine tail is the structural difference between it and exenatide.
- Also known as
- AVE0010 · ZP10
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.